Table 1 summarizes the principal characteristics of commercially approved CD19-CAR T cell therapies for B-cell lymphomas, with a focus on the molecular mechanisms underlying resistance. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.